Whalesbook
Deal Nears Amid Market Skepticism
Sun Pharmaceutical Industries is reportedly close to finalizing a $12 billion to $13 billion acquisition of assets from Organon. This global healthcare company focuses on women's health, biosimilars, and established brands. The deal, expected to be funded by debt from global banks and Sun Pharma's cash reserves, would mark a major strategic expansion. Analysts at Nomura and Macquarie have kept their 'buy' and 'outperform' ratings, pointing to improved market presence and earnings. However, investors have responded negatively. Sun Pharma's shares dropped significantly on Friday, April 24, 2026, extending a month-long decline. Technical indicators, like an RSI around 33, suggest the stock is trading near oversold levels.
High Valuation Compared to Peers
The acquisition proposal comes as Sun Pharma's valuation appears high compared to its rivals. The company's current price-to-earnings (P/E) ratio is around 35.3x-35.7x. This is notably higher than competitors like Dr. Reddy's Laboratories (17.2x-20.7x P/E), Cipla (18.9x-23.1x P/E), and Lupin (22.5x-24.2x P/E). Organon, meanwhile, seems attractively priced, with reported EV/Revenue multiples around 1.7x and EV/EBITDA near 5.5x. Organon's P/E ratio is as low as 2.4x, which may have drawn Sun Pharma's interest. However, this valuation gap prompts questions about any premium Sun Pharma might pay. Despite this, Sun Pharma has a strong balance sheet, with a debt-to-equity ratio under 7% and negative net debt, showing it can manage additional debt.
Analyst Concerns and Organon Outlook
Despite positive notes from some brokerages, caution is advised. Organon's analyst consensus leans mixed to negative, with many recommending 'Moderate Sell' or 'Reduce' and price targets indicating potential declines. While a few analysts remain positive on Organon, general sentiment is cautious. The market's negative reaction to Sun Pharma's potential bid suggests investors see execution risks and possible overvaluation. One analyst pointed out that Sun Pharma's increasing offer shows a strong push to finalize the deal, which "leaves little room for error." The strategy behind acquiring women's health and biosimilar assets is clear, but a $12-$13 billion transaction has significant financial implications. Organon's net leverage of about 4.3x adds to the risk, though the combined company's leverage is expected to stay manageable.
Strategic Move in Growing Sector
The Indian pharmaceutical sector remains active in mergers and acquisitions, with companies seeking new capabilities and specialty treatments. Sun Pharma's acquisition plan fits this trend, aiming to grow its share in women's health and biosimilars, areas with promising long-term growth. Analysts expect the Organon deal to boost earnings, projecting manageable financial impacts. Yet, the immediate market reaction shows investor hesitancy. This could be due to the deal's large size, the complexities of integrating major cross-border acquisitions, and the premium valuation Sun Pharma typically commands. The stock's recent drop, even with positive strategic news, indicates investors are focused on risks rather than just the announced plans.